Accepted for Publication: December 17, 2013.
Published Online: March 3, 2014. doi:10.1001/jamaneurol.2013.6001.
Study concept and design: Jackson, Mead, Collinge.
Acquisition of data: Edgeworth, Sicilia, Abdilahi, Korteweg, Mackey, Thomas, Wang, Schott, Mummery, Chinnery.
Analysis and interpretation of data: Jackson, Burk-Rafel, Mead, Collinge.
Drafting of the manuscript: Jackson, Burk-Rafel, Sicilia, Mead.
Critical revision of the manuscript for important intellectual content: Jackson, Burk-Rafel, Edgeworth, Abdilahi, Korteweg, Mackey, Thomas, Wang, Schott, Mummery, Chinnery, Mead, Collinge.
Statistical analysis: Burk-Rafel.
Obtained funding: Jackson, Collinge.
Administrative, technical, and material support: Jackson, Sicilia, Abdilahi, Korteweg, Mackey, Thomas, Wang, Chinnery, Mead.
Study supervision: Jackson, Sicilia, Mead, Collinge.
Conflict of Interest Disclosures: Dr Collinge is a director and Drs Collinge and Jackson are shareholders of D-Gen Ltd (London), an academic spinout company working in the field of prion disease diagnosis, decontamination, and therapeutics. No other disclosures were reported.
Funding/Support: This work was funded by the UK Medical Research Council. The UK Department of Health and the University College London Hospitals NHS Foundation Trust Biomedical Research Centre funded the National Prion Monitoring Cohort study. Some of this work was undertaken at University College London Hospital, which received a proportion of funding from the Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust, and The Wolfson Foundation. This work was supported by the National Institute for Health Research Queen Square Dementia Biomedical Research Unit. Mr Burk-Rafel is a Whitaker International Fellow. Dr Chinnery is a Wellcome Trust Senior Fellow in Clinical Science (084980/Z/08/Z).
Role of the Sponsors: The sponsors provided financial support for the research but had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the patients and families affected by neurodegenerative diseases for their support of this work and our clinical colleagues at the National CJD Research and Surveillance Centre in Edinburgh, Scotland, and across the United Kingdom with whom we coordinate patient referral and research. Particular thanks to Susan Stramer, PhD, American Red Cross Biomedical Services, and the American Red Cross for provision of samples; Gail Eglon, BSc, Institute of Genetic Medicine, Newcastle University, and Nwanyieze Nwali, BSc, Institute of Genetic Medicine, Newcastle University, who coordinated the collection of samples at the Institute of Genetic Medicine; Zoe Fox, PhD, Joint Research Office, UCL Institute of Neurology, who calculated prevalence study sample sizes; Ray Young, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology, for help preparing the figures; and Jonathan Wadsworth, PhD, MRC Prion Unit and Department of NeurodegenerativeDisease, UCL Institute of Neurology, for critically reading the manuscript. No compensation was received for these contributions.